https://www.selleckchem.com/products/dx3-213b.html
0% P = .00 for the overall response and was 1.284 (95% CI 0.889-1.855, I2 = 0.0% P = .182) for the CR and in the ipilimumab category the pooled OR was 5.440 (95% CI 2.896-10.220, I2 = 70.89% P = .001) for the overall response and was 5.169 (95% CI 3.163-8.446, I2 = 0.0% P = .00 for the CR. The incidence of any treatment-related adverse events was significantly higher in the combination group than that of the nivolumab monotherapy 4.044 (95% CI 1.740-9.403, I2 = 91.64% P = .001) or the ipilimumab monotherapy 2.465 (95% CI 0.839-7.23
Like
Comment
Share
